Boosting the VZV-Specific Memory B and T Cell Response to Prevent Herpes Zoster After Kidney Transplantation
BackgroundSolid organ transplant recipients are at high risk to develop (complicated) herpes zoster (HZ). Booster vaccination could prevent HZ. However, end-stage renal disease (ESRD) patients show poor immunological responses to vaccinations. We studied the effect of a live attenuated VZV booster v...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.927734/full |
| _version_ | 1818465877153021952 |
|---|---|
| author | Marcia M. L. Kho Willem Weimar S. Reshwan K. Malahe Joke M. Zuijderwijk Ronella de Kuiper Marieken J. Boer-Verschragen Annemiek A. van der Eijk Dennis A. Hesselink Marlies E. J. Reinders Nicole M. van Besouw |
| author_facet | Marcia M. L. Kho Willem Weimar S. Reshwan K. Malahe Joke M. Zuijderwijk Ronella de Kuiper Marieken J. Boer-Verschragen Annemiek A. van der Eijk Dennis A. Hesselink Marlies E. J. Reinders Nicole M. van Besouw |
| author_sort | Marcia M. L. Kho |
| collection | DOAJ |
| description | BackgroundSolid organ transplant recipients are at high risk to develop (complicated) herpes zoster (HZ). Booster vaccination could prevent HZ. However, end-stage renal disease (ESRD) patients show poor immunological responses to vaccinations. We studied the effect of a live attenuated VZV booster vaccine on VZV-specific B and T cell memory responses in ESRD patients and healthy controls. NL28557.000.09, www.toetsingonline.nlMethodsVZV-seropositive patients, aged ≥50 years, awaiting kidney transplantation, were vaccinated with Zostavax®. Gender and age-matched VZV-seropositive potential living kidney donors were included as controls. VZV-specific IgG titers were measured before, at 1, 3 and 12 months post-vaccination. VZV-specific B and T cell responses before, at 3 months and 1 year after vaccination were analysed by flow-cytometry and Elispot, respectively. Occurrence of HZ was assessed at 5 years post-vaccination.Results26 patients and 27 donors were included. Median VZV-specific IgG titers were significantly higher at all time-points post-vaccination in patients (mo 1: 3104 IU/ml [1967-3825], p<0.0001; mo 3: 2659 [1615-3156], p=0.0002; mo 12: 1988 [1104-2989], p=0.01 vs. pre: 1397 [613-2248]) and in donors (mo 1: 2981 [2126-3827], p<0.0001; mo 3: 2442 [2014-3311], p<0.0001; mo 12: 1788 [1368-2460], p=0.0005 vs. pre: 1034 [901-1744]. The patients’ IgG titers were comparable to the donors’ at all time-points. The ratio VZV-specific B cells of total IgG producing memory B cells had increased 3 months post-vaccination in patients (0.85 [0.65-1.34] vs. pre: 0.56 [0.35-0.81], p=0.003) and donors (0.85 [0.63-1.06] vs. pre: 0.53 [0.36-0.79], p<0.0001) and remained stable thereafter in donors. One year post-vaccination, the percentage of CD4+ central memory cells had increased in both patients (0.29 [0.08-0.38] vs. 0.12 [0.05-0.29], p=0.005) and donors (0.12 [0.03-0.37] vs. 0.09 [0.01-0.20], p=0.002) and CD4+ effector memory cells had increased in donors (0.07 [0.02-0.14] vs. 0.04 [0.01-0.12], p=0.007). Only 1 patient experienced HZ, which was non-complicated.ConclusionVZV booster vaccination increases VZV-specific IgG titers and percentage VZV-specific memory T-cells for at least 1 year both in ESRD patients and healthy controls. VZV-specific memory B cells significantly increased in patients up to 3 months after vaccination. Prophylactic VZV booster vaccination prior to transplantation could reduce HZ incidence and severity after transplantation. |
| first_indexed | 2024-04-13T20:51:34Z |
| format | Article |
| id | doaj.art-39a7faa097854fbcafbb3681e9bd4583 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-13T20:51:34Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-39a7faa097854fbcafbb3681e9bd45832022-12-22T02:30:30ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-07-011310.3389/fimmu.2022.927734927734Boosting the VZV-Specific Memory B and T Cell Response to Prevent Herpes Zoster After Kidney TransplantationMarcia M. L. Kho0Willem Weimar1S. Reshwan K. Malahe2Joke M. Zuijderwijk3Ronella de Kuiper4Marieken J. Boer-Verschragen5Annemiek A. van der Eijk6Dennis A. Hesselink7Marlies E. J. Reinders8Nicole M. van Besouw9Erasmus Medical Centre (MC) Transplant Institute, Department of Internal Medicine, University Medical Center Rotterdam, Rotterdam, NetherlandsErasmus Medical Centre (MC) Transplant Institute, Department of Internal Medicine, University Medical Center Rotterdam, Rotterdam, NetherlandsErasmus Medical Centre (MC) Transplant Institute, Department of Internal Medicine, University Medical Center Rotterdam, Rotterdam, NetherlandsErasmus Medical Centre (MC) Transplant Institute, Department of Internal Medicine, University Medical Center Rotterdam, Rotterdam, NetherlandsErasmus Medical Centre (MC) Transplant Institute, Department of Internal Medicine, University Medical Center Rotterdam, Rotterdam, NetherlandsErasmus Medical Centre (MC) Transplant Institute, Department of Internal Medicine, University Medical Center Rotterdam, Rotterdam, NetherlandsDepartment of Viroscience, Erasmus Medical Centre (MC), University Medical Centre Rotterdam, Rotterdam, NetherlandsErasmus Medical Centre (MC) Transplant Institute, Department of Internal Medicine, University Medical Center Rotterdam, Rotterdam, NetherlandsErasmus Medical Centre (MC) Transplant Institute, Department of Internal Medicine, University Medical Center Rotterdam, Rotterdam, NetherlandsErasmus Medical Centre (MC) Transplant Institute, Department of Internal Medicine, University Medical Center Rotterdam, Rotterdam, NetherlandsBackgroundSolid organ transplant recipients are at high risk to develop (complicated) herpes zoster (HZ). Booster vaccination could prevent HZ. However, end-stage renal disease (ESRD) patients show poor immunological responses to vaccinations. We studied the effect of a live attenuated VZV booster vaccine on VZV-specific B and T cell memory responses in ESRD patients and healthy controls. NL28557.000.09, www.toetsingonline.nlMethodsVZV-seropositive patients, aged ≥50 years, awaiting kidney transplantation, were vaccinated with Zostavax®. Gender and age-matched VZV-seropositive potential living kidney donors were included as controls. VZV-specific IgG titers were measured before, at 1, 3 and 12 months post-vaccination. VZV-specific B and T cell responses before, at 3 months and 1 year after vaccination were analysed by flow-cytometry and Elispot, respectively. Occurrence of HZ was assessed at 5 years post-vaccination.Results26 patients and 27 donors were included. Median VZV-specific IgG titers were significantly higher at all time-points post-vaccination in patients (mo 1: 3104 IU/ml [1967-3825], p<0.0001; mo 3: 2659 [1615-3156], p=0.0002; mo 12: 1988 [1104-2989], p=0.01 vs. pre: 1397 [613-2248]) and in donors (mo 1: 2981 [2126-3827], p<0.0001; mo 3: 2442 [2014-3311], p<0.0001; mo 12: 1788 [1368-2460], p=0.0005 vs. pre: 1034 [901-1744]. The patients’ IgG titers were comparable to the donors’ at all time-points. The ratio VZV-specific B cells of total IgG producing memory B cells had increased 3 months post-vaccination in patients (0.85 [0.65-1.34] vs. pre: 0.56 [0.35-0.81], p=0.003) and donors (0.85 [0.63-1.06] vs. pre: 0.53 [0.36-0.79], p<0.0001) and remained stable thereafter in donors. One year post-vaccination, the percentage of CD4+ central memory cells had increased in both patients (0.29 [0.08-0.38] vs. 0.12 [0.05-0.29], p=0.005) and donors (0.12 [0.03-0.37] vs. 0.09 [0.01-0.20], p=0.002) and CD4+ effector memory cells had increased in donors (0.07 [0.02-0.14] vs. 0.04 [0.01-0.12], p=0.007). Only 1 patient experienced HZ, which was non-complicated.ConclusionVZV booster vaccination increases VZV-specific IgG titers and percentage VZV-specific memory T-cells for at least 1 year both in ESRD patients and healthy controls. VZV-specific memory B cells significantly increased in patients up to 3 months after vaccination. Prophylactic VZV booster vaccination prior to transplantation could reduce HZ incidence and severity after transplantation.https://www.frontiersin.org/articles/10.3389/fimmu.2022.927734/fullbooster vaccinationherpes zosterkidney transplantationvaricella zoster virushumoral responseT-cell reactivity |
| spellingShingle | Marcia M. L. Kho Willem Weimar S. Reshwan K. Malahe Joke M. Zuijderwijk Ronella de Kuiper Marieken J. Boer-Verschragen Annemiek A. van der Eijk Dennis A. Hesselink Marlies E. J. Reinders Nicole M. van Besouw Boosting the VZV-Specific Memory B and T Cell Response to Prevent Herpes Zoster After Kidney Transplantation Frontiers in Immunology booster vaccination herpes zoster kidney transplantation varicella zoster virus humoral response T-cell reactivity |
| title | Boosting the VZV-Specific Memory B and T Cell Response to Prevent Herpes Zoster After Kidney Transplantation |
| title_full | Boosting the VZV-Specific Memory B and T Cell Response to Prevent Herpes Zoster After Kidney Transplantation |
| title_fullStr | Boosting the VZV-Specific Memory B and T Cell Response to Prevent Herpes Zoster After Kidney Transplantation |
| title_full_unstemmed | Boosting the VZV-Specific Memory B and T Cell Response to Prevent Herpes Zoster After Kidney Transplantation |
| title_short | Boosting the VZV-Specific Memory B and T Cell Response to Prevent Herpes Zoster After Kidney Transplantation |
| title_sort | boosting the vzv specific memory b and t cell response to prevent herpes zoster after kidney transplantation |
| topic | booster vaccination herpes zoster kidney transplantation varicella zoster virus humoral response T-cell reactivity |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.927734/full |
| work_keys_str_mv | AT marciamlkho boostingthevzvspecificmemorybandtcellresponsetopreventherpeszosterafterkidneytransplantation AT willemweimar boostingthevzvspecificmemorybandtcellresponsetopreventherpeszosterafterkidneytransplantation AT sreshwankmalahe boostingthevzvspecificmemorybandtcellresponsetopreventherpeszosterafterkidneytransplantation AT jokemzuijderwijk boostingthevzvspecificmemorybandtcellresponsetopreventherpeszosterafterkidneytransplantation AT ronelladekuiper boostingthevzvspecificmemorybandtcellresponsetopreventherpeszosterafterkidneytransplantation AT mariekenjboerverschragen boostingthevzvspecificmemorybandtcellresponsetopreventherpeszosterafterkidneytransplantation AT annemiekavandereijk boostingthevzvspecificmemorybandtcellresponsetopreventherpeszosterafterkidneytransplantation AT dennisahesselink boostingthevzvspecificmemorybandtcellresponsetopreventherpeszosterafterkidneytransplantation AT marliesejreinders boostingthevzvspecificmemorybandtcellresponsetopreventherpeszosterafterkidneytransplantation AT nicolemvanbesouw boostingthevzvspecificmemorybandtcellresponsetopreventherpeszosterafterkidneytransplantation |